ClinicalTrials.gg
Active, not recruitingNCT06450197AMALTHEAUpdated Nov 10, 2026

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

A Phase 2 interventional study of AZD7798 and Placebo in Moderate to Severe Crohn's Disease, sponsored by AstraZeneca. Active, not recruiting at 116 sites in 26 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Crohn Disease by AstraZeneca — none open to participants now, 2 under way, none of them phase 3. Crohn Disease · AstraZeneca.

Enrollment
3rd of 13
120 · median 48
Started
2024
with 2 others
Phase 2
5 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Crohn Disease by AstraZeneca, this one is the 3rd largest by enrollment, is one of 3 that started in 2024, is one of 5 in phase 2, and was the 11th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 13 studies in Crohn Disease by AstraZeneca is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Crohn Disease by AstraZeneca as a file.
02

Study summary

This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.

03

Conditions studied

  • Moderate to Severe Crohn's Disease

Keywords

  • Crohn disease
  • Inflammation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 80 years of age.
  2. Diagnosis of Crohn's disease established with verifiable clinical, AND at least one of imaging, endoscopic and/or histopathologic evidence.
  3. Moderate to severe active Crohn's disease.
  4. Ileal/ileocecal (L1), colonic (L2), or ileocolonic (L3) disease, as classified based on the localisation of active inflammation.
  5. Capable of giving signed .
  6. A history of at least one of:

    1. Intolerance or inadequate response to conventional treatment (oral , azathioprine, 6-mercaptopurine, or methotrexate), biologics, or other approved advanced therapy (eg, JAK inhibitors) OR
    2. Corticosteroid dependency (defined as inability to taper below budesonide 6 mg/day or prednisolone 10 mg/day equivalent dosing without recurrent active disease) for the treatment of Crohn's disease.

Exclusion criteria

Exclusion Criteria:

  1. Evidence, or clinical suspicion, of other forms of IBD or concomitant additional active gastrointestinal luminal inflammatory diseases.
  2. Symptomatic strictures or bowel stenoses, or strictures preventing passage of endoscope throughout the colon (including at screening endoscopy).
  3. Any complications of Crohn's disease where surgery is anticipated or planned prior to end of study treatment.
  4. Evidence of extensive prior gastrointestinal surgical interventions.
  5. Within 3 months prior to screening endoscopy visit:

    1. History of toxic megacolon
    2. Diagnosis of peritonitis or need for treatment of peritonitis
    3. Bowel perforation or evidence of obstruction.
  6. All intrabdominal abscesses are excluded. Cutaneous and perianal/perirectal abscesses and fistulae are excluded unless adequately drained at least 4 weeks prior to screening endoscopy visit with no anticipation for surgery prior to end of study treatment.
  7. Ongoing or expected nutritional dependency on total enteral or parenteral nutrition during study.
  8. Evidence of an increased risk of colorectal cancer.
  9. Symptomatic oral Crohn's disease within one year.
  10. Any of the following treatments within the specified time period prior to screening endoscopy visit

    1. An anti-TNF biologic within 8 weeks prior to screening endoscopy visit
    2. Any biologic targeting immune response other than an anti-TNF within 12 weeks prior to screening endoscopy visit
    3. Other advanced small molecule treatments for Crohn's disease within 4 weeks prior to screening endoscopy visit
    4. Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, or tacrolimus (FK-506) within 4 weeks prior to screening endoscopy visit
    5. Treatment with apheresis within 4 weeks prior to screening endoscopy visit
    6. Administration of any within 4 weeks prior to screening endoscopy visit to end of study
    7. Faecal microbiota transplantation within 4 weeks prior to screening endoscopy visit
    8. Lymphocyte-depleting treatment within 12 months prior to screening endoscopy visit
    9. Any previous exposure to AZD7798.
  11. Any initiation or changes in dosing of the following medications prior to screening endoscopy visit as outlined: (a) 5-aminosalicylates within 2 weeks (b) Oral within 2 weeks or stable doses of steroids exceeding the following dose equivalents: (i) Systemic steroids > 20 mg/day or prednisolone equivalent (ii) Steroids with limited systemic effects (eg, budesonide and beclomethasone), exceeding maximum budesonide dose equivalent (9 mg/day) (c) Immunomodulators within 4 weeks (d) Antibiotic therapy for the treatment of Crohn's disease (e) Probiotics within 2 weeks.
  12. Chronic use of nonsteroidal anti-inflammatory drugs.
  13. Evidence of recent or currently active infection, including use of IV or oral antibiotics for documented infection within 30 days prior to screening endoscopy visit.
  14. Evidence of chronic or .
  15. History of TB (active or latent) unless an appropriate course of treatment has been completed.
  16. Positive diagnostic TB test at screening.
  17. History of serious opportunistic infection within 12 months prior to screening endoscopy visit.
  18. CMV colitis within previous 12 months prior to screening endoscopy visit.
  19. Positive C. difficile toxin stool test at screening.
  20. Symptomatic herpes zoster infection within 3 months prior to screening endoscopy.
  21. Any identified immunodeficiency.
  22. Abnormal laboratory results at screening suggesting participation may be unsafe, which will prevent the patient from completing the study, or will interfere with the interpretation of the study results.
  23. Reproduction:

    1. Pregnant and breastfeeding patients, or those planning to breastfeed during the study
    2. FOCBP unless completely abstinent or using a highly effective and barrier method of contraception.
  24. Prolonged interval.
  25. cardiovascular conditions.
  26. Current or history of malignancy.
  27. Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, haematological disease, hepatic disease, renal disease, gastrointestinal disease or other major disease other than active Crohn's disease.
  28. Current enrolment in another interventional study or treatment with any drug within 4 months prior to screening endoscopy visit.
  29. Unstable lifestyle factors.
  30. Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  31. Investigator concerns regarding patient's willingness and ability to attend all study visits, comply with the study procedures, read in order to complete questionnaires, or to complete the study period
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    AZD7798

    AZD7798

    Drug: AZD7798

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • AZD7798

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. CDAI remission

    Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. It is based on: number of loose stools, abdominal pain, general well-being, extraintestinal complications, antidiarrheal agents used in the previous 7 days, abdominal mass felt on palpation, hematocrit and body weight

    Time frame: Week 12

Secondary outcomes

  1. Endoscopic response

    Simple Endoscopic Score for Crohn's Disease (SES-CD) is based on the evaluation of five defined bowel segments (rectum, sigmoid + descending colon, transverse colon, ascending colon, and terminal ileum), and in these segments the presence and size of ulcerations and the extent of the inflammatory area and stenosis are assessed

    Time frame: Week 12

  2. Endoscopic remission

    Simple Endoscopic Score for Crohn's Disease (SES-CD) is based on the evaluation of five defined bowel segments (rectum, sigmoid + descending colon, transverse colon, ascending colon, and terminal ileum), and in these segments the presence and size of ulcerations and the extent of the inflammatory area and stenosis are assessed

    Time frame: Week 12

  3. Endoscopic score change from baseline

    Simple Endoscopic Score for Crohn's Disease (SES-CD) is based on the evaluation of five defined bowel segments (rectum, sigmoid + descending colon, transverse colon, ascending colon, and terminal ileum), and in these segments the presence and size of ulcerations and the extent of the inflammatory area and stenosis are assessed

    Time frame: Week 12

  4. CDAI response

    Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. It is based on: number of loose stools, abdominal pain, general well-being, extraintestinal complications, antidiarrheal agents used in the previous 7 days, abdominal mass felt on palpation, hematocrit and body weight

    Time frame: Week 12

  5. CDAI score change from baseline

    Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. It is based on: number of loose stools, abdominal pain, general well-being, extraintestinal complications, antidiarrheal agents used in the previous 7 days, abdominal mass felt on palpation, hematocrit and body weight

    Time frame: Week 12

  6. Symptomatic remission

    Decrease of average daily stool frequency and average daily abdominal pain

    Time frame: Week 12

  7. Serum AZD7798 concentration

    Serum AZD7798 concentration (PK)

    Time frame: Up to 85 days

  8. Incidence of anti-drug antibody response

    Incidence of anti-drug antibody (ADA) response - number and percentages with a positive ADA result

    Time frame: Up to 36 weeks

  9. Titre of anti-drug antibody response

    Titre of anti-drug antibody (ADA) response - immunogenicity titre will be summarized descriptively as a continuous variable, only for ADA positive tests

    Time frame: Up to 36 weeks

07

Study locations

116 sites
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Escondido, California 92025, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    Orlando, Florida 32825, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Clinton Township, Michigan 48038, United States
  • Research Site
    St Louis, Missouri 63156, United States
  • Research Site
    Asheville, North Carolina 28803, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Uniontown, Pennsylvania 15401, United States
  • Research Site
    Garland, Texas 75044, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    CABA, 1125, Argentina
  • Research Site
    CABA, C1025ABI, Argentina
  • Research Site
    Ciudad Autonoma de Bs As, C1013AAB, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1128, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Fitzroy, 3065, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Wollongong, 2500, Australia
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Campinas, 13092133, Brazil
  • Research Site
    Jaú, 17201-130, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Santo André, 09080-110, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 04077020, Brazil
  • Research Site
    Gorna Oryahovitsa, 5100, Bulgaria
  • Research Site
    Sofia, 1680, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Lethbridge, Alberta T1J4G9, Canada
  • Research Site
    Santiago, 7500010, Chile
  • Research Site
    Santiago, 7691236, Chile
  • Research Site
    Santiago, 8330034, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510655, China
  • Research Site
    Hangzhou, 310016, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Montpellier, 34090, France
  • Research Site
    Pierre-Bénite, 69495, France
  • Research Site
    Berlin, 14163, Germany
  • Research Site
    Potsdam, 14467, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Békéscsaba, 5600, Hungary
  • Research Site
    Gyöngyös, 3200, Hungary
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20157, Italy
  • Research Site
    Roma, 00152, Italy
  • Research Site
    Rome, 00168, Italy
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Kashiwa-shi, 277-0871, Japan
  • Research Site
    Kure-shi, 737-8505, Japan
  • Research Site
    Minatoku, 108-8642, Japan
  • Research Site
    Nagasaki, 852-8501, Japan
  • Research Site
    Nagoya, 466-8560, Japan
  • Research Site
    Sakura-shi, 285-8741, Japan
  • Research Site
    Sapporo, 060-8543, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Johor Bahru, 80100, Malaysia
  • Research Site
    Kota Bharu, 15586, Malaysia
  • Research Site
    Kota Kinabalu, 88200, Malaysia
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Amsterdam, 1081 HZ, Netherlands
  • Research Site
    Bydgoszcz, 85-229, Poland
  • Research Site
    Chojnice, 89-600, Poland
  • Research Site
    Krakow, 30-363, Poland
  • Research Site
    Lublin, 20-582, Poland
  • Research Site
    Poznan, 60-529, Poland
  • Research Site
    Poznan, 61-731, Poland
  • Research Site
    Sopot, 81-756, Poland
  • Research Site
    Warsaw, 00-189, Poland
  • Research Site
    Warsaw, 04-501, Poland
  • Research Site
    Wroclaw, 53-149, Poland
  • Research Site
    Bucharest, 020125, Romania
  • Research Site
    Cluj-Napoca, 400380, Romania
  • Research Site
    Timișoara, 300002, Romania
  • Research Site
    Košice, 04013, Slovakia
  • Research Site
    Nitra, 94901, Slovakia
  • Research Site
    Prešov, 08001, Slovakia
  • Research Site
    Trnava, 91702, Slovakia
  • Research Site
    Assagay, 3610, South Africa
  • Research Site
    Plumstead, 7800, South Africa
  • Research Site
    Barcelona, 08022, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Linköping, 58185, Sweden
  • Research Site
    Stockholm, 11630, Sweden
  • Research Site
    New Taipei City, 24352, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Ankara, 06800, Turkey (Türkiye)

Showing the first 100 of 116 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Apr 2026, 20 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 20 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
Jun 10, 2024
StartActual
Aug 28, 2024
Primary completionActual
Apr 30, 2026
CompletionEst.
May 14, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 27, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06450197
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
Aug 28, 2024
Primary completion
Apr 30, 2026
Completion
May 14, 2027 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD7798

Start the discussion